WHO ICTRP trial
A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY…
JPRN-jRCT2080222323 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080222323 |
|---|---|
| Public title | A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION |
| Scientific title | A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING… |
| Primary sponsor | Chugai Pharmaceutical Co., Ltd. |
| Secondary sponsors | F. Hoffmann-La Roche Ltd |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Non-Small Cell Lung Cancer |
| Interventions | investigational material(s) Generic name etc : Onartuzumab[MetMAb, PRO143966] + Erlotinib[Tarceva] INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational… |
| Registration date | Oct 12, 2013 |
| Target size | 300 |
| Secondary IDs | JapicCTI-132373 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: